Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 36 for your search:

Drug:  bendamustine hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Randomized Study of Fludarabine Phosphate, Cyclophosphamide, and Rituximab Versus Bendamustine Hydrochloride and Rituximab in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL10, CLL10, EUDRACT-2007-007587-21, EU-20883, ROCHE-GCLLSG-CLL10, NCT00769522

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C18083/3064/NL/MN, NCT00877006

Bendamustine in Acute Leukemia and MDS

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2007-0634, NCT00790855

Phase I/II Study of Bendamustine Hydrochloride and Erlotinib Hydrochloride in Patients With Triple-Receptor-Negative, Stage IIIB, IIIC, or IV Breast Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-08164, OSU 08164, 2008C0131, NCCN-C03, NCT00834678

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: F080929010, UAB 0818, NCT00856830

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C18083/1063/MM/US, NCT00920855

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AGMT CLL-6 BendAlem, NCT00951457

Phase I/II Study of Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Who Are Not Eligible for High-Dose Chemotherapy With Autologous Stem Cell Transplantation

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-38/08, SAKK 38/08, EUDRACT-2009-012559-67, EU-20976, NCT00987493

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: NLG-MCL4, NCT00963534

10.

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: RBP-01/08, OSHO77, NCT01002703

11.

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: Haema CBF SCLC UK/AS 02, NCT00168922

12.

Phase II Study of Bendamustine and Rituximab in Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL2M, EU-20552, EUDRACT-2005-001596-34, ROCHE-GCLLSG-CLL2M, NCT00274989

13.

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OSHO #73, NCT00385125

14.

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-041, NCT00705250

15.

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)

Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: 08-LEUK-07-MCC/CI, NCT00758693

16.

Phase II Study of Bendamustine Hydrochloride in Patients With Recurrent or Progressive Anaplastic Glioma or Glioblastoma Multiforme

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UWCC-6803, UWCC-6803, FHCRC-6803, IR-6803, NCT00823797, NCCN-C01

17.

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PI-08904, IND Exemption Number 103985, NCT00831597

18.

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ULYM07054, NCT00547534

19.

Open Trial of Bendamustine HCL in Women With Advanced Ovarian Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-1137-04, NCT00867503

20.

Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C18083/2039/NL/US-CA, NCT00891839

21.

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2008-0204, NCT00901927

22.

Phase II Study of Bendamustine Hydrochloride and Rituximab in Patients With Refractory B-Cell Chronic Lymphocytic Leukemia

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0902, S0902, NCT00939328

23.

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HO08405, RV-CLL/SLL-PI-397, NCT00974233

24.

Phase II Study of Second-Line Bendamustine in Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-THO-0920, VICCTHO0920, NCT00984542

25.

Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VI-1903, EudraCT 2009-009912-34, NCT00992134

Select All on Page

Help with Results

A Service of the National Cancer Institute